Table 3.
Formulation | E.E. (%) |
D.L. (%) |
---|---|---|
pCMV-βGal-CS NCs | 90.6 ± 0.9 | 36.2 ± 0.4 |
pCMV-βGal-HA/CS NCs | 89.0 ± 4.8 | 35.6 ± 1.9 |
Formulation | E.E. (%) |
D.L. (%) |
---|---|---|
pCMV-βGal-CS NCs | 90.6 ± 0.9 | 36.2 ± 0.4 |
pCMV-βGal-HA/CS NCs | 89.0 ± 4.8 | 35.6 ± 1.9 |